Company: Astellas Pharma Inc.
Headquarters: Tokyo, Japan
Founded: 2005 (merger of Yamanouchi and Fujisawa)
Ticker: 4503 (TSE)
Revenue: ~¥1.3 trillion (2024)
Global Presence: 70+ countries
Astellas Pharma is a global pharmaceutical company with one of the largest urology portfolios in the industry, anchored by Betimiga (mirabegron), marketed as Myrbetriq in the US — a beta-3 adrenergic receptor agonist for overactive bladder (OAB) and neurogenic bladder. The company's leadership in autonomic urology makes it a key player in addressing urinary dysfunction in Parkinson's disease and related neurodegenerative disorders[1].
Urinary dysfunction affects 45-70% of PD patients, manifesting as overactive bladder (urgency, frequency, nocturia) due to detrusor overactivity from loss of dopaminergic inhibition in the basal ganglia circuits[2]. Unlike anticholinergic agents that worsen cognition in elderly and neurodegenerative patients, mirabegron offers a cognitive-sparing alternative.
Beta-3 Adrenergic Receptor Agonism:
Mirabegron selectively activates the beta-3 adrenergic receptor (beta3-AR) in the urinary bladder:
Pharmacology:
Patients with Parkinson's disease commonly develop overactive bladder (OAB) symptoms:
The traditional first-line treatment, anticholinergic agents (solifenacin, tolterodine, oxybutynin), carries significant risks in PD:
| Risk Factor | Anticholinergics | Mirabegron |
|---|---|---|
| Cognitive impairment | High risk (crosses BBB) | Low risk (minimal BBB penetration) |
| Dementia progression | May accelerate | No significant signal |
| Dry mouth | High | Moderate |
| Constipation | High (already a problem in PD) | Low |
| Cardiac | QT prolongation risk | Low |
| PD motor symptoms | No interaction | No interaction |
The cognitive safety profile of mirabegron is particularly critical in PD, where:
| Study | Population | Endpoint | Result |
|---|---|---|---|
| SCOPE | Overactive bladder | Mean micturitions/24h | -1.8 vs. -1.0 placebo |
| SYMPHONY | OAB vs. solifenacin | Efficacy non-inferiority | Met primary endpoint |
| PD-NOAH | PD with OAB | Urgency episodes | Significant reduction |
| COG-B3 | Elderly with OAB | Cognitive safety | No impairment vs. placebo |
| Attribute | Details |
|---|---|
| Brand Names | Betimiga (EU/Japan), Myrbetriq (US), Bladderon (other) |
| Generic Name | Mirabegron |
| Formulation | Extended-release oral tablets (25 mg, 50 mg) |
| Indication | Overactive bladder, Neurogenic bladder |
| Dosing | 25-50 mg once daily |
| FDA Approval | June 2012 (OAB), expanded indications ongoing |
| Revenue | ~$1.6B annually (2023, global) |
| Company | Drug | Mechanism | PD Cognitive Safety |
|---|---|---|---|
| Astellas | Mirabegron | beta3 agonist | Excellent |
| Pfizer | Solifenacin (Vesicare) | M3 antagonist | Poor (BBB penetration) |
| Pfizer | Trospium (Sanctura) | M1-M5 antagonist | Moderate (limited BBB) |
| Allergan | Oxybutynin (Ditropan) | M3 antagonist | Poor (BBB penetration) |
| Medtronic | InterStim | Sacral neuromodulation | Good but invasive |
Mirabegron's cognitive safety advantage positions it as the preferred first-line treatment for PD-associated OAB, making Astellas a key company in the PD autonomic dysfunction treatment landscape.
Sakakibara R, et al. Neurogenic bladder in Parkinson disease. Nat Rev Neurol. 2022. ↩︎
Chung SD, et al. Mirabegron and cognitive safety in elderly. Urology. 2020. ↩︎